{
    "title": "115_hr5687",
    "content": "The Act is titled the \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act.\" It introduces safety-enhancing packaging and disposal features for certain drugs. The Secretary may issue an order requiring the holder of a covered application to implement technologies for packaging or disposal of drugs to mitigate abuse or misuse, including reducing the availability of unused drugs. Prior consultation is required before issuing such an order. The Secretary may issue an order for packaging or disposal technologies to reduce drug abuse, with consultation required with stakeholders. Technologies must be proportionate to the risk of abuse and not overly restrictive on patient access. The Secretary may issue an order for packaging or disposal technologies to reduce drug abuse, with consultation required with stakeholders. The order may provide options for implementing or modifying technologies and incorporate standards for packaging or disposal. The Secretary may issue an order for packaging or disposal technologies to reduce drug abuse, with consultation required with stakeholders. Orders may be based on nationally or internationally recognized standards and may apply to specific drug classes after consultation with relevant stakeholders. The Secretary may issue orders for packaging or disposal technologies to reduce drug abuse, based on recognized standards and consultation with stakeholders. Holders of covered applications must submit proposed changes to comply with the order within 180 days or a longer period specified by the Secretary. Holders of covered applications must implement approved changes within 90 calendar days after approval, or a longer period determined by the Secretary. The Secretary may approve a longer period for implementing changes in a covered application if requested, and alternative measures for packaging, storage, or disposal can be proposed and approved. The Secretary may approve alternative technologies, controls, or measures in a supplement if supported by data to mitigate drug abuse. Disputes can be resolved using specified procedures. The Secretary may approve alternative technologies, controls, or measures in a supplement to mitigate drug abuse, with disputes resolved using specified procedures. Definitions for 'covered application' and 'relevant stakeholders' are provided in this section. The term 'relevant stakeholders' includes various experts and organizations within the drug manufacturing industry, such as brand and generic drug manufacturers, wholesalers, payers, healthcare providers, pharmacists, poison centers, and government agencies like the CDC and DEA, among others. The Federal Food, Drug, and Cosmetic Act is being amended to include new provisions regarding drug approval requirements and the content of Abbreviated New Drug Applications. The Federal Food, Drug, and Cosmetic Act is being amended to include new provisions regarding drug approval requirements and the content of Abbreviated New Drug Applications. The amendments include requirements for opioid-containing drugs in schedule II or III to have proposed technologies, controls, or measures related to packaging or disposal that provide comparable protections. The Federal Food, Drug, and Cosmetic Act is being amended to include new provisions for drug approval requirements. Section 505(j)(4) is amended to include grounds for refusing to approve an Abbreviated New Drug Application, including specific requirements for opioid-containing drugs. The Federal Food, Drug, and Cosmetic Act is being amended to include new provisions for drug approval requirements, specifically for opioid-containing drugs. The amended section 505(j)(4) outlines grounds for refusing to approve an Abbreviated New Drug Application, including requirements related to packaging and disposal technologies to mitigate abuse or misuse risks. The amended Federal Food, Drug, and Cosmetic Act includes provisions for drug approval requirements, particularly for opioid-containing drugs. An abbreviated new drug application must describe differences from the reference listed drug due to section 505-2, without being seen as changes to labeling not allowed under the Act. The amended Federal Food, Drug, and Cosmetic Act includes provisions for drug approval requirements, particularly for opioid-containing drugs. An abbreviated new drug application must describe differences from the reference listed drug without being seen as changes to labeling not allowed under the Act. Additionally, for covered applications submitted under subsection (j) of section 505, subsection (j)(2)(A) shall not limit the type of data the Secretary of Health and Human Services may request for making determinations under section 505-2. The Comptroller General of the United States will submit a report to Congress within 12 months of the enactment of the Act, detailing the effectiveness of in-home controlled substance disposal products and identifying barriers to their use by patients and consumers. The report to Congress will detail the availability and barriers to use of disposal products and packaging technologies, as well as federal oversight of in-home controlled substance disposal products. The report to Congress will include a description of federal oversight of controlled substance packaging technologies, including the agencies involved and recommended technologies such as unit dose packaging. The report to Congress will include recommendations on whether site-of-use, in-home controlled substance disposal products and packaging technologies require Federal oversight and which agencies should be responsible for such oversight. The report to Congress will include recommendations on the approval and evaluation of products or technologies, as well as the potential role of the Federal Government in ensuring product efficacy. The House of Representatives passed the bill on June 19, 2018. Karen L. Haas attested to it as the Clerk."
}